STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $45,238,000 | +73.3% | 1,343,956 | +100.0% | 0.29% | -10.9% |
Q1 2021 | $26,100,000 | -37.3% | 671,978 | 0.0% | 0.33% | -26.2% |
Q4 2020 | $41,616,000 | +84.9% | 671,978 | 0.0% | 0.45% | +35.9% |
Q3 2020 | $22,505,000 | +40.5% | 671,978 | 0.0% | 0.33% | +27.0% |
Q2 2020 | $16,013,000 | +4.1% | 671,978 | 0.0% | 0.26% | -35.4% |
Q1 2020 | $15,388,000 | -19.1% | 671,978 | 0.0% | 0.40% | +6.1% |
Q4 2019 | $19,030,000 | +31.8% | 671,978 | 0.0% | 0.38% | -2.8% |
Q3 2019 | $14,440,000 | -26.3% | 671,978 | 0.0% | 0.39% | -13.6% |
Q2 2019 | $19,601,000 | – | 671,978 | – | 0.45% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 16,786,713 | $391,802,000 | 74.38% |
RTW INVESTMENTS, LP | 3,544,248 | $84,459,000 | 2.38% |
Cormorant Asset Management, LP | 1,701,292 | $40,542,000 | 1.55% |
Redmile Group, LLC | 2,502,306 | $59,630,000 | 1.10% |
RA Capital Management | 1,119,963 | $26,689,000 | 0.52% |
HighVista Strategies LLC | 17,734 | $423,000 | 0.35% |
GILDER GAGNON HOWE & CO LLC | 1,569,564 | $37,403,000 | 0.29% |
Birchview Capital, LP | 20,000 | $477,000 | 0.29% |
Perceptive Advisors | 671,978 | $16,013,000 | 0.26% |
Artal Group S.A. | 285,000 | $6,792,000 | 0.19% |